Exploring the Role of HNRNPA3 in Breast Cancer Progression, Immune Microenvironment, and Therapeutic Sensitivity: A Multiomics and Functional Prediction Study
Human Mutation · 2026-01 · 2026 (1)
DOI: 10.1155/humu/5519745 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Mutation, online erschienen am 03.05.2026. Verfasst von Lijie Gong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China, zchospital.com. Hauptthemen laut MEDLINE: Tumor Microenvironment, Breast Neoplasms, Heterogeneous-Nuclear Ribonucleoprotein Group A-B. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Education of Zhejiang Province, Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Background
Breast invasive carcinoma (BRCA) remains a leading cause of female cancer mortality, necessitating novel biomarkers and therapeutic targets. Heterogeneous nuclear ribonucleoprotein A3 (HNRNPA3) emerges as a potential regulator in tumor progression and immune modulation, yet its comprehensive role in BRCA remains uncharacterized.
Methods
We conducted an integrated multiomics analysis of HNRNPA3 in BRCA using data from TCGA, GEO datasets, single‐cell RNA sequencing, and spatial transcriptomics. Bioinformatics approaches included differential expression analysis, survival analysis, functional enrichment, immune microenvironment characterization, and drug sensitivity prediction.
Results
HNRNPA3 was significantly upregulated in BRCA tissues and correlated with advanced tumor grade, metastasis, and poor prognosis across multiple cohorts. Functional enrichment revealed HNRNPA3′s involvement in cell cycle regulation and immune‐related pathways. Immune profiling demonstrated that high HNRNPA3 expression was associated with altered immune cell distribution, particularly CD4+ T cells, and reduced immunotherapy response. Spatial transcriptomics confirmed predominant HNRNPA3 expression in malignant regions. Drug sensitivity analysis identified potential therapeutic agents (CD‐437 and talazoparib) targeting HNRNPA3‐associated pathways.
Conclusion
HNRNPA3 functions as a critical oncogenic regulator in BRCA by promoting tumor progression through cell cycle dysregulation and immune microenvironment remodeling. Its strong association with therapy resistance positions HNRNPA3 as both a prognostic biomarker and promising therapeutic target for breast cancer intervention strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China, zchospital.com.
- Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China, cas.cn.
- Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China, zchospital.com.
- Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China, hznu.edu.cn.
- School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China, hznu.edu.cn.
- Cancer Center, Department of Thoracic Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China, hznu.edu.cn.
ORCID-Profile: Weihui Guo, Weiliang Feng
Förderung
- Department of Education of Zhejiang Province
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Gong, L., Xu, Y., Guo, W., Cai, X., Zhang, F., Ma, J., Tao, H., & Feng, W. (2026). Exploring the Role of HNRNPA3 in Breast Cancer Progression, Immune Microenvironment, and Therapeutic Sensitivity: A Multiomics and Functional Prediction Study. Human Mutation, 2026(1). https://doi.org/10.1155/humu/5519745
Vancouver
Gong L, Xu Y, Guo W, Cai X, Zhang F, Ma J, et al. Exploring the Role of HNRNPA3 in Breast Cancer Progression, Immune Microenvironment, and Therapeutic Sensitivity: A Multiomics and Functional Prediction Study. Human Mutation. 2026;2026(1). doi:10.1155/humu/5519745
BibTeX
@article{Gong2026,
author = {Gong, Lijie and Xu, Yang and Guo, Weihui and Cai, Xufan and Zhang, Fanrong and Ma, Jie and Tao, Houquan and Feng, Weiliang},
title = {Exploring the Role of HNRNPA3 in Breast Cancer Progression, Immune Microenvironment, and Therapeutic Sensitivity: A Multiomics and Functional Prediction Study},
journal = {Human Mutation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/humu/5519745}
}
EUVIMED